Andrew Satlin
Chief Medical Officer
Andy brings > 20 years of drug development experience and a focus on novel clinical and statistical methods for neurodegenerative disorders. He was EVP and CMO at Intra-Cellular Therapies, held positions at Eisai and Novartis, and was Assistant Professor of Psychiatry at Harvard Medical School and Director of Geriatric Psychiatry at McLean Hospital.
Chief Medical Officer in Transposon Therapeutics
Transformational therapies for neurodegenerative and aging-related diseases
Andrew Satlin
Chief Medical Officer